Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
NCT ID: NCT00839540
Last Updated: 2024-04-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
21 participants
INTERVENTIONAL
2008-12-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities.
This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
NCT00105144
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
NCT00189709
Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
NCT00665639
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
NCT00083343
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
NCT01213823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients - Adult patients with presumptive candidemia. Patients with severe neutropenia (\<500) APACHE II scores \> 20, or significant liver disease will be excluded. All will give written informed consent (Pappas et al. CID. Oct 1, 2007).
Drugs - Patients will receive either CFG: 70 mg loading dose (LD) followed by 50 mg once daily (qd) (8 patients), MFG: 100 mg qd (8 patients) or MFG: 200 mg qd (8 patients). All agents will be given by slow IV infusion (MFG will be supplied by Astellas).
Sera - Blood samples will be collected at the end of the infusion (peak) and at 12 h and 24 h (trough) after the beginning of an infusion (day 3-4).
Each patients sera will be tested (MIC and cidal activity) against their own Candida isolate (if isolated). In addition, recent clinical isolates of C. glabrata will also be tested against patient sera (time-kill) to verify previous in vitro and animal PD studies (Cota. AAC. Nov. 2006; Wiederhold. AAC. May 2007).
Results:
* Patient outcome, including Candida eradication, will be documented for each patient by repeat culture.
* Serum concentrations (lab to be determined) and PK analysis of each echinocandin will be determined for each patient.
* Serum cidal titers will be measured against each of the Candida isolates for each agent at each time period. Median and geometric mean Peak and duration of cidal activity will then be determined and compared.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
micafungin 100
Patients receive Micafungin 100 mg qd
micafungin
100 mg qd by slow IV infusion for 24 h
micafungin 200
Patients receive 200 mg Micafungin qd
Micafungin
200 mg qd by slow IV infusion for 24 h
Caspofungin
Patients receive caspofungin 70 mg LD followed by 50 mg qd
Caspofungin
70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
micafungin
100 mg qd by slow IV infusion for 24 h
Micafungin
200 mg qd by slow IV infusion for 24 h
Caspofungin
70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with APACHE II scores \> 20
* Patients with severe liver disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma US, Inc.
INDUSTRY
Gary E. Stein, Pharm.D.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gary E. Stein, Pharm.D.
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary E Stein, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
Michigan State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sparrow Hospital
Lansing, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA-07-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.